Arkolith/Insider Trading/SILO/Form 4

Weisblum Eric

Chief Executive Officer, DirectorSilo Pharma, Inc. (SILO) · full profile →Form 4 · filed Dec 16, 2025
Net Buying
Open-Market Buys
$2K
Open-Market Sells
$0
Net Open-Market Flow
$2K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 15, 2025Buy(P)3K$0.42$1K217K
Dec 15, 2025Buy(P)3K$0.41$1K214K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001213900-25-122429) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML